Search

Your search keyword '"Scheipl, Susanne"' showing total 39 results
Start Over Author "Scheipl, Susanne" Publication Year Range Last 10 years
39 results on '"Scheipl, Susanne"'

16. Zwei Geschlechter, ein Bewegungsapparat? Geschlecht und Gender als Einflussfaktoren in der Orthopädie

Author

Scheipl, Susanne, Rásky, Eva, Kortendiek, Beate, Series editor, Lenz, Ilse, Series editor, Lutz, Helma, Series editor, Mae, Michiko, Series editor, Meuser, Michael, Series editor, Müller, Ursula, Series editor, Oechsle, Mechtild, Series editor, Riegraf, Birgit, Series editor, Sabisch, Katja, Series editor, Villa, Paula-Irene, Series editor, Völker, Susanne, Series editor, Hornberg, Claudia, editor, Pauli, Andrea, editor, and Wrede, Birgitta, editor

Published
2016
Full Text
View/download PDF

17. Gender Mainstreaming rund um die Gesundheit : Entwicklungen, Status quo und Zukunftsperspektiven in Österreich

Author

Rásky, Eva, Scheipl, Susanne, Kortendiek, Beate, Series editor, Lenz, Ilse, Series editor, Lutz, Helma, Series editor, Mae, Michiko, Series editor, Meuser, Michael, Series editor, Müller, Ursula, Series editor, Oechsle, Mechtild, Series editor, Riegraf, Birgit, Series editor, Sabisch, Katja, Series editor, Villa, Paula-Irene, Series editor, Völker, Susanne, Series editor, Hornberg, Claudia, editor, Pauli, Andrea, editor, and Wrede, Birgitta, editor

Published
2016
Full Text
View/download PDF

19. Prognostic Impact of Pulmonary Metastasectomy in Bone Sarcoma Patients: A Retrospective, Single-Centre Study

Author

Smolle, Maria Anna, primary, Kogler, Angelika, additional, Andreou, Dimosthenis, additional, Scheipl, Susanne, additional, Bergovec, Marko, additional, Castellani, Christoph, additional, Till, Holger, additional, Benesch, Martin, additional, Posch, Florian, additional, Szkandera, Joanna, additional, Smolle-Jüttner, Freyja-Maria, additional, and Leithner, Andreas, additional

Published
2023
Full Text
View/download PDF

20. Implementation of Copy Number Variations-Based Diagnostics in Morphologically Challenging EWSR1/FUS::NFATC2 Neoplasms of the Bone and Soft Tissue

Author

Brcic, Iva, primary, Scheipl, Susanne, additional, Bergovec, Marko, additional, Leithner, Andreas, additional, Szkandera, Joanna, additional, Sotlar, Karl, additional, Suda, Arnold, additional, Smolle, Maria Anna, additional, Kraus, Tanja, additional, Rosenberg, Andrew Eric, additional, Liegl-Atzwanger, Bernadette, additional, and Igrec, Jasminka, additional

Published
2022
Full Text
View/download PDF

21. Targeting epigenetic features in clear cell sarcomas based on patient-derived cell lines

Author

Karner, Christina, primary, Anders, Ines, additional, Vejzovic, Djenana, additional, Szkandera, Joanna, additional, Scheipl, Susanne, additional, Deutsch, Alexander J A, additional, Weiss, Larissa, additional, Vierlinger, Klemens, additional, Kolb, Dagmar, additional, Kühberger, Stefan, additional, Heitzer, Ellen, additional, Habisch, Hansjörg, additional, Zhang, Fangrong, additional, Madl, Tobias, additional, Reininger-Gutmann, Birgit, additional, Liegl-Atzwanger, Bernadette, additional, and Rinner, Beate, additional

Published
2022
Full Text
View/download PDF

22. Oligometastases: what is the evidence for aggressive local treatment?

Author

Wittig, Ulrike, Andreou, Dimosthenis, Scheipl, Susanne, Friesenbichler, Jörg, Bergovec, Marko, and Leithner, Andreas

Subjects
Medicine and health
Abstract

Objectives: Metastatic disease is generally considered incurable. The aim of therapy is therefore usually disease control, prolongation of life and palliation of symptoms. The definition of "oligometastases" was first described in 1995 by Hellman and Weichselbaum as metastases limited in the [for full text, please go to the a.m. URL]

Published
2022
Full Text
View/download PDF

23. Leben orthopädisch/traumatologische Patient*innen in einer VUCA-Welt?

Author

Reinbacher, Patrick, Überwimmer, Michaela, Mörkl, Sabrina, Scheipl, Susanne, Leithner, Andreas, and Fischerauer, Stefan

Subjects
Klarheit, Vision, Komplexität, Medicine and health, Valatilität, VUCA, Ambiguität
Abstract

Fragestellung: Wenn Patient*innen dazu bewegt werden Ambulanzen oder Ordinationen aufzusuchen, so erfolgt dies meist nicht als Reaktion auf Symptome, sondern aufgrund von begleitenden emotionalen Empfindungen. Der Beweggrund kann dabei unterschiedlich sein. Oft herrschen Unsicherheiten über [zum vollständigen Text gelangen Sie über die oben angegebene URL]

Published
2022
Full Text
View/download PDF

24. Musculoskeletal tuberculosis revisited: bone and joint tuberculosis in Austria

Author

Vielgut, Ines, primary, Putzl, Lisa, additional, Thomüller, Ingrid, additional, Igrec, Jasminka, additional, Brcic, Iva, additional, Valentin, Thomas, additional, Wittig, Ulrike, additional, Zettl, Richard, additional, Sadoghi, Patrick, additional, Leithner, Andreas, additional, Fischerauer, Stefan, additional, and Scheipl, Susanne, additional

Published
2022
Full Text
View/download PDF

25. Survival Prediction in Patients Treated Surgically for Metastases of the Appendicular Skeleton—An External Validation of 2013-SPRING Model

Author

Smolle, Maria Anna, primary, Musser, Ewald, additional, Bergovec, Marko, additional, Friesenbichler, Joerg, additional, Wibmer, Christine Linda, additional, Leitner, Lukas, additional, Sørensen, Michala Skovlund, additional, Petersen, Michael Mørk, additional, Brcic, Iva, additional, Szkandera, Joanna, additional, Scheipl, Susanne, additional, and Leithner, Andreas, additional

Published
2022
Full Text
View/download PDF

26. Survival Prediction in Patients Treated Surgically for Metastases of the Appendicular Skeleton—An External Validation of 2013-SPRING Model

Author

Smolle, Maria Anna, Musser, Ewald, Bergovec, Marko, Friesenbichler, Joerg, Wibmer, Christine Linda, Leitner, Lukas, Sørensen, Michala Skovlund, Petersen, Michael Mørk, Brcic, Iva, Szkandera, Joanna, Scheipl, Susanne, Leithner, Andreas, Smolle, Maria Anna, Musser, Ewald, Bergovec, Marko, Friesenbichler, Joerg, Wibmer, Christine Linda, Leitner, Lukas, Sørensen, Michala Skovlund, Petersen, Michael Mørk, Brcic, Iva, Szkandera, Joanna, Scheipl, Susanne, and Leithner, Andreas

Abstract

Introduction: The aim of this study was to externally validate the 2013-SPRING model, a survival prediction tool for patients treated surgically for bone metastases in a retrospective patient cohort from a single institution. Moreover, subgroup analyses on patients treated with (A) endoprostheses or (B) osteosynthesis, as well as (C) upper limb and (D) lower limb metastases, were performed. Methods: Altogether, 303 cancer patients (mean age: 67.6 ± 11.1 years; 140 males (46.2%)) with bone metastases to the extremities, treated surgically between March 2000 and June 2018 at a single tertiary sarcoma centre, were retrospectively included. Median follow-up amounted to 6.3 (interquartile range (IQR): 2.3–21.8) months, with all patients followed-up for at least one year or until death. The 2013-SPRING model was applied to assess the prognostication accuracy at 3, 6 and 12 months. Models were validated with area under the curve receiver operator characteristic (AUC ROC; the higher the better), as well as Brier score. Results: Of the 303 patients, 141 had been treated with osteosynthesis (46.5%), and the remaining 162 patients with endoprosthesis (53.5%). Sixty-five (21.5%) metastases were located in the upper limbs, and two hundred and thirty-eight (78.5%) in the lower limbs. Using the 2013-SPRING model for the entire cohort, the accuracy of risk of death prediction at 3, 6 and 12 months, determined by the AUC ROC, was 0.782 (95% CI: 0.729–0.843), 0.810 (95% CI: 0.763–0.858) and 0.802 (95% CI: 0.751–0.854), respectively. Corresponding Brier scores were 0.170, 0.178 and 0.169 at 3, 6 and 12 months. In the subgroup analyses, predictive accuracy of the 2013-SPRING model was likewise encouraging, albeit being slightly higher in the osteosynthesis subgroup as compared with the endoprosthesis subgroup, and also higher in the upper limb in comparison to the lower limb metastasis subgroup. Conclusions: The current validation study of the 2013-SPRING model shows that this model

Published
2022

29. Molecular profiling of soft-tissue sarcomas with FoundationOne® Heme identifies potential targets for sarcoma therapy: a single-centre experience

Author

Scheipl, Susanne, primary, Brcic, Iva, additional, Moser, Tina, additional, Fischerauer, Stefan, additional, Riedl, Jakob, additional, Bergovec, Marko, additional, Smolle, Maria, additional, Posch, Florian, additional, Gerger, Armin, additional, Pichler, Martin, additional, Stoeger, Herbert, additional, Leithner, Andreas, additional, Heitzer, Ellen, additional, Liegl-Atzwanger, Bernadette, additional, and Szkandera, Joanna, additional

Published
2021
Full Text
View/download PDF

30. Influence of tumor-infiltrating immune cells on local control rate, distant metastasis, and survival in patients with soft tissue sarcoma

Author

Smolle, Maria A, primary, Herbsthofer, Laurin, additional, Goda, Mark, additional, Granegger, Barbara, additional, Brcic, Iva, additional, Bergovec, Marko, additional, Scheipl, Susanne, additional, Prietl, Barbara, additional, El-Heliebi, Amin, additional, Pichler, Martin, additional, Gerger, Armin, additional, Posch, Florian, additional, Tomberger, Martina, additional, López-García, Pablo, additional, Feichtinger, Julia, additional, Baumgartner, Claudia, additional, Leithner, Andreas, additional, Liegl-Atzwanger, Bernadette, additional, and Szkandera, Joanna, additional

Published
2021
Full Text
View/download PDF

31. Molecular profiling of soft-tissue sarcomas with FoundationOne ® Heme identifies potential targets for sarcoma therapy: a single-centre experience.

Author

Scheipl, Susanne, Brcic, Iva, Moser, Tina, Fischerauer, Stefan, Riedl, Jakob, Bergovec, Marko, Smolle, Maria, Posch, Florian, Gerger, Armin, Pichler, Martin, Stoeger, Herbert, Leithner, Andreas, Heitzer, Ellen, Liegl-Atzwanger, Bernadette, and Szkandera, Joanna

Abstract

Background: Molecular diagnosis has become an established tool in the characterisation of adult soft-tissue sarcomas (STS). FoundationOne® Heme analyses somatic gene alterations in sarcomas via DNA and RNA-hotspot sequencing of tumour-associated genes. Methods: We evaluated FoundationOne® Heme testing in 81 localised STS including 35 translocation-associated and 46 complex-karyotyped cases from a single institution. Results: Although FoundationOne® Heme achieved broad patient coverage and identified at least five genetic alterations in each sample, the sensitivity for fusion detection was rather low, at 42.4%. Nevertheless, potential targets for STS treatment were detected using the FoundationOne® Heme assay: complex-karyotyped sarcomas frequently displayed copy-number alterations of common tumour-suppressor genes, particularly deletions in TP53, NF1, ATRX, and CDKN2A. A subset of myxofibrosarcomas (MFS) was amplified for HGF (n = 3) and MET (n = 1). PIK3CA was mutated in 7/15 cases of myxoid liposarcoma (MLS; 46.7%). Epigenetic regulators (e.g. MLL2 and MLL3) were frequently mutated. Conclusions: In summary, FoundationOne® Heme detected a broad range of genetic alterations and potential therapeutic targets in STS (e.g. HGF/MET in a subset of MFS, or PIK3CA in MLS). The assay's sensitivity for fusion detection was low in our sample and needs to be re-evaluated in a larger cohort. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

32. Broadening the spectrum of NTRKrearranged mesenchymal tumors and usefulness of pan-TRK immunohistochemistry for identification of NTRKfusions

Author

Brcic, Iva, Godschachner, Theresa Maria, Bergovec, Marko, Igrec, Jasminka, Till, Holger, Lackner, Herwig, Scheipl, Susanne, Kashofer, Karl, Brodowicz, Thomas, Leithner, Andreas, Szkandera, Joanna, and Liegl-Atzwanger, Bernadette

Abstract

Fusions involving NTRK1, NTRK2, and NTRK3are oncogenic drivers occurring in a spectrum of mesenchymal neoplasms ranging from benign to highly malignant tumors. To gain further insights into the staining profile with the pan-TRK assay, we analyzed a large number of soft tissue sarcomas and correlated our findings with molecular testing. Additionally, we expand the spectrum of NTRK-fusion tumors by reporting a mesenchymal lesion in the lung as well as a mesenchymal skin lesion in the spectrum of benign fibrous histiocytoma with NTRK—fusion. We retrospectively reviewed soft tissue sarcomas diagnosed at the Diagnostic and Research Institute of Pathology, Medical University of Graz, between 1999 and 2019, and cases from the consultation files of one of the authors (BLA). In total, 494 cases were analyzed immunohistochemically with pan-TRK antibody (clone EPR17341, RTU, Roche/Ventana) and positive cases (defined as any cytoplasmic/nuclear staining in more than 1% of tumor cells) underwent next-generation sequencing (NGS). Immunohistochemical staining was observed in 16 (3.2%) cases. Eleven cases with focal weak and moderate cytoplasmic/membranous or focal moderate to strong nuclear staining did not harbor an NTRK-fusion (three synovial sarcomas, three leiomyosarcomas, two extraskeletal myxoid chondrosarcomas, and one each: dedifferentiated liposarcoma, pleomorphic liposarcoma, and myxofibrosarcoma). Four cases showed strong diffuse nuclear and/or cytoplasmatic staining, and one case showed diffuse, but weak cytoplasmic staining. All these cases demonstrated an NTRK-fusion (LMNA-NTRK1, IRF2BP2-NTRK1, TMB3-NTRK1, ETV6-NTRK3, RBPMS-NTRK3). Pan-TRK assay (clone EPR17341, RTU, Roche, Ventana) immunohistochemistry serves as a reliable diagnostic marker that can also be expressed in non-NTRK-rearranged mesenchymal neoplasms. It can be used as a surrogate marker for identification of NTRKfusion, nevertheless, an RNA-based NGS for detection of the specific fusion should be performed to confirm the rearrangement, if patients are undergoing targeted therapy. Additionally, we identified NTRK-fusion-positive, primary mesenchymal tumors of the lung and the skin.

Published
2021
Full Text
View/download PDF

33. EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen: Focused Compound Screen in Chordoma

Author

Barnard, Michelle, Guppy, Naomi, Drewry, David H., Scheipl, Susanne, Möller, Peter, Leithner, Andreas, Turlais, Fabrice, Leite, Ana P., Ye, Hongtao, Zuercher, William J., Jorgensen, Mette, Smith, James A., Amary, Fernanda, Cottone, Lucia, Strauss, Sandra J., Pillay, Nischalan, Flanagan, Adrienne M., Brüderlein, Silke, and Tirabosco, Roberto

Abstract

Chordoma is a rare malignant bone tumour with a poor prognosis and limited therapeutic options. We undertook a focused compound screen (FCS) against 1097 compounds on three well-characterized chordoma cell lines; 154 compounds were selected from the single concentration screen (1 µm), based on their growth-inhibitory effect. Their half-maximal effective concentration (EC50 ) values were determined in chordoma cells and normal fibroblasts. Twenty-seven of these compounds displayed chordoma selective cell kill and 21/27 (78%) were found to be EGFR/ERBB family inhibitors. EGFR inhibitors in clinical development were then studied on an extended cell line panel of seven chordoma cell lines, four of which were sensitive to EGFR inhibition. Sapitinib (AstraZeneca) emerged as the lead compound, followed by gefitinib (AstraZeneca) and erlotinib (Roche/Genentech). The compounds were shown to induce apoptosis in the sensitive cell lines and suppressed phospho-EGFR and its downstream pathways in a dose-dependent manner. Analysis of substituent patterns suggested that EGFR-inhibitors with small aniline substituents in the 4-position of the quinazoline ring were more effective than inhibitors with large substituents in that position. Sapitinib showed significantly reduced tumour growth in two xenograft mouse models (U-CH1 xenograft and a patient-derived xenograft, SF8894). One of the resistant cell lines (U-CH2) was shown to express high levels of phospho-MET, a known bypass signalling pathway to EGFR. Neither amplifications (EGFR, ERBB2, MET) nor mutations in EGFR, ERBB2, ERBB4, PIK3CA, BRAF, NRAS, KRAS, PTEN, MET or other cancer gene hotspots were detected in the cell lines. Our findings are consistent with the reported (p-)EGFR expression in the majority of clinical samples, and provide evidence for exploring the efficacy of EGFR inhibitors in the treatment of patients with chordoma and studying possible resistance mechanisms to these compounds in vitro and in vivo. © 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.

Published
2016
Full Text
View/download PDF

34. Undifferentiated round cell sarcomas with CIC-DUX4gene fusion: expanding the clinical spectrum

Author

Brčić, Iva, Brodowicz, Thomas, Cerroni, Lorenzo, Kashofer, Karl, Serbanescu, Georgia Luiza, Kasseroler, Maria Theresia, Amann, Gabriele, Scheipl, Susanne, Szkandera, Joanna, Leithner, Andreas, and Liegl-Atzwanger, Bernadette

Abstract

Round cell sarcomas are a heterogeneous group of mesenchymal neoplasms with overlapping morphology and immunohistochemical profile. Ewing sarcoma is the most well-known tumour in this group characterised by EWSR1/FUSrearrangements with members of the ETS family of transcription factors. Undifferentiated round cell sarcomas lacking these rearrangements, known as ‘Ewing-like’ sarcomas, usually show atypical clinical presentation and focal CD99 positivity. This group of tumours can be subdivided into: capicua transcriptional repressor (CIC)-rearranged sarcomas, Bcl6 corepressor (BCOR)-rearranged sarcomas, sarcomas with EWSR1fusion to non-ETS family members and unclassified round cell sarcomas.

Published
2020
Full Text
View/download PDF

35. EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen

Author

Scheipl, Susanne, primary, Barnard, Michelle, additional, Cottone, Lucia, additional, Jorgensen, Mette, additional, Drewry, David H, additional, Zuercher, William J, additional, Turlais, Fabrice, additional, Ye, Hongtao, additional, Leite, Ana P, additional, Smith, James A, additional, Leithner, Andreas, additional, Möller, Peter, additional, Brüderlein, Silke, additional, Guppy, Naomi, additional, Amary, Fernanda, additional, Tirabosco, Roberto, additional, Strauss, Sandra J, additional, Pillay, Nischalan, additional, and Flanagan, Adrienne M, additional

Published
2016
Full Text
View/download PDF

36. Mutation Analysis of Nine Chordoma Specimens by Targeted Next-Generation Cancer Panel Sequencing

Author

Fischer, Carina, primary, Scheipl, Susanne, additional, Zopf, Agnes, additional, Niklas, Norbert, additional, Deutsch, Alexander, additional, Jorgensen, Mette, additional, Lohberger, Birgit, additional, Froehlich, Elke Verena, additional, Leithner, Andreas, additional, Gabriel, Christian, additional, Liegl-Atzwanger, Bernadette, additional, and Rinner, Beate, additional

Published
2015
Full Text
View/download PDF

39. Management of Congenital Fourth Brachymetatarsia by Additive Autologous Lengthening Osteotomy (AALO): A Case Series.

Author

Smolle, Elisabeth, Scheipl, Susanne, Leithner, Andreas, and Radl, Roman

Abstract

The article presents a case report of a novel operative technique called the additive autologous lengthening osteotomy (AALO) of the fourth metatarsal bone performed on four patients with congenital brachymetatarsia undergoing 1-stage intercalary bone grafting. Topics discussed include details of the surgical procedure, the satisfaction expressed by the four patients, review of findings from related research and the conclusion about the safety and convenience of the technique.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results